XML 31 R20.htm IDEA: XBRL DOCUMENT v3.26.1

SEGMENT REPORTING (Tables)

3 Months Ended

Mar. 31, 2026

SEGMENT REPORTING

Schedule of Additional disaggregated significant segment expenses

​	​	​	​	​	​	​
​	​	Three Months Ended March 31
​	​ ​ ​	2026		​ ​ ​	2025
R&D Employee Expenses		$	2,065		$	1,717
R&D Clinical Trial Expenses	​	​	1,212		​	1,036
R&D Professional Fees	​	​	—	​	​	13
R&D Manufacturing	​	​	829	​	​	476
R&D License Fees	​	​	—	​	​	438
G&A Professional Fees	​	​	1,157	​	​	957
G&A Employee Expenses	​	​	601	​	​	502
G&A Insurance and other		​	396	​	​	429
Other Segment Items *		​	(210)		​	(236)
Segment Loss	​	$	6,050		$	5,332

* - Other Segment Items included in net loss includes finance income.

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration